on August 8, 2002
Published online before print August 8, 2002, doi: 10.1161/01.ATV.0000032676.20514.8F
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 10, 2002
Accepted on July 29, 2002
Administration of Recombinant P-Selectin Glycoprotein Ligand Fc Fusion Protein Suppresses Inflammation and Neointimal Formation in Zucker Diabetic Rat Model
Zhongmin Zhou ;
From the Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio.
* To whom correspondence should be addressed. E-mail: wangk{at}ccf.org.
Objective—P-selectin
mediated leukocyte-endothelium and leukocyte-platelet interaction has been reported after vascular injury and has been correlated with neointimal hyperplasia, but its role in neointimal formation after arterial injury in diabetes has not been described.
Methods and Results—Using a Zucker diabetic rat balloon injury model, we examined the role of P-selectin in the vascular inflammatory process and neointimal formation after balloon injury. Immunohistochemistry revealed that P-selectin was intensely expressed and that CD45-positive leukocyte infiltration was significantly increased after arterial injury. A single preprocedural intravenous administration of a recombinant P-selectinsoluble glycoprotein ligand-Ig inhibited CD45-positive leukocyte accumulation and suppressed neointimal formation in the Zucker diabetic rat model.
Conclusions—These results suggest that reduction of P-selectinmediated leukocyte activation with the use of recombinant P-selectinsoluble glycoprotein ligand-Ig decreases the inflammatory response and limits neointimal formation after balloon injury in diabetes.
Key words: P-selectin • diabetes mellitus • restenosis • balloon injury
This article has been cited by other articles:
 |
|
 |
|
  P. W. Bedard, V. Clerin, N. Sushkova, B. Tchernychev, T. Antrilli, C. Resmini, J. C. Keith Jr., J. K. Hennan, N. Kaila, S. DeBernardo, et al. Characterization of the Novel P-Selectin Inhibitor PSI-697 [2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] Quinoline-4-carboxylic acid] in Vitro and in Rodent Models of Vascular Inflammation and Thrombosis J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 497 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wang, Z. Zhou, M. Zhang, L. Fan, F. Forudi, X. Zhou, W. Qu, A. M. Lincoff, A. M. Schmidt, E. J. Topol, et al. Peroxisome Proliferator-Activated Receptor {gamma} Down-Regulates Receptor for Advanced Glycation End Products and Inhibits Smooth Muscle Cell Proliferation in a Diabetic and Nondiabetic Rat Carotid Artery Injury Model J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Pei, J. Gu, P.-R. Thimmalapura, A. Mison, and J. L. Nadler Activation of the 12-lipoxygenase and signal transducer and activator of transcription pathway during neointima formation in a model of the metabolic syndrome Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E92 - E102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wang, X. Zhou, Z. Zhou, N. Mal, L. Fan, M. Zhang, A. M. Lincoff, E. F. Plow, E. J. Topol, and M. S. Penn Platelet, Not Endothelial, P-Selectin Is Required for Neointimal Formation After Vascular Injury Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1584 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Coller Leukocytosis and Ischemic Vascular Disease Morbidity and Mortality: Is It Time to Intervene? Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 658 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhang, D. Chaturvedi, L. Jaggar, D. Magnuson, J. M. Lee, and T. B. Patel Regulation of Vascular Smooth Muscle Cell Proliferation and Migration by Human Sprouty 2 Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 533 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Shah Inflammation, Neointimal Hyperplasia, and Restenosis: As the Leukocytes Roll, the Arteries Thicken Circulation, May 6, 2003; 107(17): 2175 - 2177. [Full Text] [PDF]
|
|